Interleukin 2 low dose - Beijing ShuangLu Pharmaceutical/Peking University

Drug Profile

Interleukin 2 low dose - Beijing ShuangLu Pharmaceutical/Peking University

Alternative Names: hrIL-2; Recombinant human IL-2

Latest Information Update: 17 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beijing ShuangLu Pharmaceutical; Peking University
  • Developer Beijing ShuangLu Pharmaceutical; Monash University; Peking University
  • Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 29 Sep 2015 Efficacy and pharmacodynamics data from a phase II trial in Systemic lupus erythematosus released by Peking University
  • 01 Jun 2015 Phase-II clinical trials in Sjogren's syndrome in China (SC) (NCT02464319)
  • 01 Jun 2015 Phase-II clinical trials in Systemic lupus erythematosus in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top